Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 4 de 4
Filtrar
Mais filtros

Bases de dados
Tipo de documento
Assunto da revista
País de afiliação
Intervalo de ano de publicação
1.
Am J Transplant ; 14(10): 2406-11, 2014 Oct.
Artigo em Inglês | MEDLINE | ID: mdl-25146250

RESUMO

Human cytomegalovirus (HCMV) is an important pathogen in lung transplant recipients (LTRs). In LTRs, HCMV may replicate in the transplanted lung, and this is indicated by HCMV DNA detection in the bronchoalveolar lavage fluid (BALF). Local replication may occur without causing clinical symptoms or, in some patients, it may lead to symptomatic HCMV disease. In the present study, we analyzed whether HCMV replication in the allograft induces CXCL-16, a chemokine that may play a key role in the regulation of mucosal immunity, and investigated whether CXCL-16 levels in BALF can be used to differentiate LTRs with asymptomatic HCMV replication from patients who simultaneously develop disease. In total, BALF samples from 57 LTRs, of whom 8 developed HCMV disease, were assessed for CXCL-16 levels using a quantitative enzyme-linked immunosorbent assay. We found that HCMV replication in the lung triggered a significant rise in CXCL-16 levels in the BALF (p < 0.001, Wilcoxon signed-rank test). Furthermore, the CXCL-16 increase, induced by HCMV, was significantly lower in LTRs who did not develop HCMV disease (p < 0.001, Mann-Whitney U-test). Thus, CXCL-16 is a potential marker that may contribute to identify those LTRs in whom local HCMV replication in the lung remains asymptomatic.


Assuntos
Quimiocinas CXC/metabolismo , Citomegalovirus/fisiologia , Transplante de Pulmão , Receptores Depuradores/metabolismo , Replicação Viral , Líquido da Lavagem Broncoalveolar , Quimiocina CXCL16 , Ensaio de Imunoadsorção Enzimática , Humanos , Estudos Retrospectivos
2.
Med Klin Intensivmed Notfmed ; 113(3): 174-183, 2018 04.
Artigo em Alemão | MEDLINE | ID: mdl-27241777

RESUMO

Acute liver failure (ALF) is a rare condition with fatal outcome. Characteristic is rapid onset of liver damage without preexisting liver diseases, including hepatic encephalopathy and coagulopathy. Early and correct diagnosis is essential for further management of patients, since diagnosis impacts therapy choice. Survival of patients with ALF has improved dramatically due to advances in critical care medicine and the use of liver transplantation.


Assuntos
Encefalopatia Hepática , Falência Hepática Aguda , Transplante de Fígado , Cuidados Críticos , Humanos , Falência Hepática Aguda/diagnóstico , Falência Hepática Aguda/terapia
3.
Med Klin Intensivmed Notfmed ; 111(5): 447-52, 2016 Jun.
Artigo em Alemão | MEDLINE | ID: mdl-26070920

RESUMO

Interactions between the hepatic portal and cardiovascular systems are frequently found in patients with liver disease. Cirrhotic cardiomyopathy (CCMP) is defined as reduced cardiac function in patients with liver cirrhosis in the absence of other known causes of cardiac disease. The typical hyperdynamic circulatory state by means of increased cardiac output and reduced systemic vascular resistance may mask left ventricular failure. Portopulmonary hypertension (POPH) is defined as increased pulmonary arterial pressure and the presence of portal hypertension, and is associated with increased mortality. Targeted medical therapies include vasodilators such as prostanoids, endothelin receptor antagonists and phosphodiesterase-5 inhibitors. Hypoxic or ischaemic hepatitis (HH) is defined by a sharp increase of serum aminotransferase levels due to liver cell necrosis as result of cardiac, circulatory or respiratory failure. An overview of these diseases is provided in this article.


Assuntos
Cardiomiopatias/complicações , Cardiomiopatias/fisiopatologia , Cirrose Hepática/complicações , Cirrose Hepática/fisiopatologia , Débito Cardíaco/fisiologia , Cardiomiopatias/diagnóstico , Cardiomiopatias/terapia , Terapia Combinada , Diagnóstico Diferencial , Humanos , Hipertensão Portal/complicações , Hipertensão Portal/diagnóstico , Hipertensão Portal/fisiopatologia , Hipertensão Portal/terapia , Hipertensão Pulmonar/complicações , Hipertensão Pulmonar/diagnóstico , Hipertensão Pulmonar/fisiopatologia , Hipertensão Pulmonar/terapia , Unidades de Terapia Intensiva , Cirrose Hepática/diagnóstico , Cirrose Hepática/terapia , Prognóstico , Resistência Vascular/fisiologia , Disfunção Ventricular Esquerda/complicações , Disfunção Ventricular Esquerda/diagnóstico , Disfunção Ventricular Esquerda/fisiopatologia , Disfunção Ventricular Esquerda/terapia
4.
Med Klin Intensivmed Notfmed ; 109(4): 228-34, 2014 May.
Artigo em Alemão | MEDLINE | ID: mdl-24770888

RESUMO

Liver dysfunction is frequently observed in critically ill patients. Its occurrence is associated with high morbidity and mortality. The most frequent entities of hepatic dysfunction in the intensive care unit are shock liver and cholestatic liver dysfunction with incidence rates up to 10 and 30 %, respectively.Both conditions are frequently triggered by hypoxic and/or ischemic events, most commonly cardiogenic shock and sepsis/septic shock. However, several other potential contributors have been identified especially for cholestatic liver dysfunction. Apart from chronic liver diseases and malignancies, iatrogenic factors such as total parenteral nutrition, high pressure ventilation, surgical procedures, drugs and blood transfusions promote its occurrence.In shock liver and in cholestatic liver disease, early detection and therapy of the underlying disease is the only established treatment.


Assuntos
Colestase/fisiopatologia , Colestase/terapia , Cuidados Críticos/métodos , Falência Hepática/fisiopatologia , Falência Hepática/terapia , Insuficiência de Múltiplos Órgãos/fisiopatologia , Insuficiência de Múltiplos Órgãos/terapia , Diagnóstico Precoce , Humanos , Fígado/fisiopatologia , Falência Hepática/etiologia , Insuficiência de Múltiplos Órgãos/etiologia , Prognóstico
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA